PhII fail­ure in rare neu­rode­gen­er­a­tive dis­ease? No mat­ter, Bio­gen will mo­tor on in Alzheimer's

Bio­gen’s fierce fo­cus on dis­or­ders of the brain has hit an­oth­er road­block.

On Fri­day, the US drug­mak­er — which re­cent­ly res­ur­rect­ed its amy­loid-tar­get­ing Alzheimer’s drug …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.